Overview A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002) Status: Terminated Trial end date: 2009-05-01 Target enrollment: Participant gender: Summary A single dose study to assess the safety, tolerability, pharmacokinetics and pharmacokinetics of MK6349 in Type 2 Diabetics. Phase: Phase 1 Details Lead Sponsor: Merck Sharp & Dohme Corp.